Nivolumab immunotherapy helps patients with advanced bladder cancer

(University of Texas M. D. Anderson Cancer Center) The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.